心脏ATTR淀粉样变性中的常规心力衰竭治疗
该研究回顾性分析2000至2022年间英国国家淀粉样变性中心2371例ATTR-CA患者,评估心衰药物处方模式、剂量、停药率及与预后的关联。结果显示β受体阻滞剂和ACEi/ARB停药率高,而MRA停药率低;倾向评分匹配分析提示MRA与全因死亡风险降低独立相关,低剂量β受体阻滞剂在LVEF≤40%亚组中与死亡风险降低相关。
要点
- ATTR-CA患者中心衰药物处方率随心脏表型严重程度增加而升高。
- β受体阻滞剂和ACEi/ARB停药率较高,而MRA停药率较低。
- MRA与全因死亡风险降低独立相关,低剂量β受体阻滞剂在LVEF≤40%患者中与死亡风险降低相关。
核心结论
- 常规心衰药物在ATTR-CA中处方不广泛,接受治疗者心脏疾病更严重。
- β受体阻滞剂和ACEi/ARB常被停用,但低剂量β受体阻滞剂在LVEF≤40%患者中与死亡风险降低相关。
- MRA很少被停用,且与整体人群死亡风险降低相关,但需前瞻性随机对照试验确认。
研究设计与样本
- 回顾性分析2000至2022年英国国家淀粉样变性中心连续诊断为ATTR-CA的2371例患者。
主要发现
- β受体阻滞剂处方率55.4%,ACEi/ARB处方率57.4%,MRA处方率39.0%。
- 中位随访27.8个月(IQR 10.6-51.3)期间,21.7%停用β受体阻滞剂,32.9%停用ACEi/ARB,仅7.5%停用MRA。
- ACEi/ARB治疗未发现令人信服的差异。
临床怎么用
- 在ATTR-CA患者中可考虑使用MRA,因其与死亡风险降低相关且停药率低。
- 对LVEF≤40%的ATTR-CA患者,低剂量β受体阻滞剂可能与死亡风险降低相关。
- ACEi/ARB在ATTR-CA中的获益缺乏令人信服的证据,且停药率较高。
局限性
- 回顾性研究设计。
- MRA和β受体阻滞剂的获益需前瞻性随机对照试验确认。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: The aims of this study were to assess prescription patterns, dosages, discontinuation rates, and association with prognosis of conventional heart failure medications in patients with transthyretin cardiac amyloidosis (ATTR-CA). METHODS AND RESULTS: A retrospective analysis of all consecutive patients diagnosed with ATTR-CA at the National Amyloidosis Centre between 2000 and 2022 identified 2371 patients with ATTR-CA. Prescription of heart failure medications was greater among patients with a more severe cardiac phenotype, comprising beta-blockers in 55.4%, angiotensin-converting enzyme inhibitors (ACEis)/angiotensin II receptor blockers (ARBs) in 57.4%, and mineralocorticoid receptor antagonists (MRAs) in 39.0% of cases. During a median follow-up of 27.8 months (interquartile range 10.6-51.3), 21.7% had beta-blockers discontinued, and 32.9% had ACEi/ARBs discontinued. In contrast, only 7.5% had MRAs discontinued. A propensity score-matched analysis demonstrated that treatment with MRAs was independently associated with a reduced risk of mortality in the overall population [hazard ratio (HR) 0.77 (95% confidence interval (CI) 0.66-0.89), P < .001] and in a pre-specified subgroup of patients with a left ventricular ejection fraction (LVEF) >40% [HR 0.75 (95% CI 0.63-0.90), P = .002]; and treatment with low-dose beta-blockers was independently associated with a reduced risk of mortality in a pre-specified subgroup of patients with a LVEF ≤40% [HR 0.61 (95% CI 0.45-0.83), P = .002]. No convincing differences were found for treatment with ACEi/ARBs. CONCLUSION: Conventional heart failure medications are currently not widely prescribed in ATTR-CA, and those that received medication had more severe cardiac disease. Beta-blockers and ACEi/ARBs were often discontinued, but low-dose beta-blockers were associated with reduced risk of mortality in patients with a LVEF ≤40%. In contrast, MRAs were rarely discontinued and were associated with reduced risk of mortality in the overall population; but these findings require confirmation in prospective randomized controlled trials.
引用
- Ioannou, Massa, Patel, et al. Conventional heart failure therapy in cardiac ATTR amyloidosis. Eur Heart J. 2023. PMID: 37216684. doi:10.1093/eurheartj/ehad347
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。